News
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute
QIAGEN übertrifft Ausblick für zweites Quartal und erhöht Prognose für das Gesamtjahr 2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das zweite Quartal 2022 bekannt und hob die Prognose für das Gesamtjahr 2022 an.
Der Konzernumsatz sank im
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
Net sales for Q2 2022 declined 9% (-4% at
DGAP-Adhoc: MagForce AG: Application for the Opening of Insolvency Proceedings
DGAP-News: Burcon to Present at the Canaccord Genuity 42nd Annual Growth Conference
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 4, 2022, following the release of its second
DGAP-News: Burcon NutraScience Corp.: Burcon JV, Merit Functional Foods Launches New Peazazz C Pea Protein Ingredient
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has been used to interpret more than three million
QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass mit QIAGEN Clinical Insights (QCI), der unternehmenseigenen Plattform zur Unterstützung klinischer Entscheidungsfindungen
Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities